United States is world’s largest spender on healthcare at an estimated 16% of GDP in 2010. This spending is likely to continue to grow at a faster pace in the light of healthcare reforms of 2010 that extended insurance to around 45.7 million residents. United States is the single largest pharmaceutical market globally, accounting for more than 40% of the world's pharmaceutical sales. Over the past two years, however, the U.S. pharmaceutical industry has faced a number of macroeconomic challenges and industry specific issues such as inflation, government healthcare policy, declining levels of innovation, patent losses, among others. The pharmaceutical market in United States is estimated at US$338 billion, growing at 2.5% since 2009 and at a CAGR of 4.5% since 2004. Prescription drugs account for the largest share (88.6%) of total pharmaceutical sales followed by OTC drugs (8.2%) and Alternative Medication (3.2%).
Synergyst’s “United States Pharmaceutical Sector Report (2011 Edition)” is a comprehensive assessment of to the U.S. pharmaceutical market and the trends that are prevailing in the market. Report analyses healthcare, economic and policy environment in the country and presents the SWOT analysis of the country’s pharmaceutical sector. Dynamics of the industry are presented by evaluating the industry structure and estimation of market size, both in terms of volume and dollar value. Market sizing and forecast is provided for the overall market and all the segments from 2005 to 2015. Report also looks at trends that are impacting the pharmaceutical sales in United States and assess the competitive landscape in the industry.